Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University.
Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint
Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
MK6482-012: An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Gurney, H., Chapman, N. & Zhang, A.
11/02/21 → 26/11/26
Project: Research
-
Keynote B61: MK3475-B61 - A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
Gurney, H., Chapman, N. & Tan, P.
1/02/21 → 10/12/25
Project: Research
-
Bayer 20510: A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH
Gurney, H. & Chapman, N.
1/12/20 → 10/09/25
Project: Research
-
AMPLITUDE: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Gurney, H. & Chapman, N.
30/11/20 → 15/10/25
Project: Research
-
MK6842-013: Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
Gurney, H., Zhang, A. & Chapman, N.
13/11/20 → 15/10/25
Project: Research
Research Outputs
-
Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?
Al-Mansouri, L., Arasaratnam, M. & Gurney, H., Mar 2021, In: European Journal of Hospital Pharmacy. 28, 2, p. 83-87 10 p.Research output: Contribution to journal › Article › peer-review
-
High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial
Nair-Shalliker, V., Smith, D. P., Gebski, V., Patel, M. I., Frydenberg, M., Yaxley, J. W., Gardiner, R., Espinoza, D., Kimlin, M. G., Fenech, M., Gillatt, D., Woo, H., Armstrong, B. K., Rasiah, K., Awad, N., Symons, J. & Gurney, H., 2 Mar 2021, In: BMJ Open. 11, 3, p. 1-9 9 p., e044055.Research output: Contribution to journal › Article › peer-review
Open AccessFile14 Downloads (Pure) -
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
Motzer, R., Alekseev, B., Rha, S-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., Kozlov, V., Alyasova, A., Hong, S-H., Kapoor, A., Alonso Gordoa, T., Merchan, J. R., Winquist, E., Maroto, P., Goh, J. C., Kim, M. & 19 others, , 8 Apr 2021, In: New England Journal of Medicine. 384, 14, p. 1289-1300 12 p.Research output: Contribution to journal › Article › peer-review
42 Citations (Scopus) -
Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center
Arasaratnam, M., Balakrishnar, B., Crumbaker, M., Turner, S., Hayden, A. J., Brooks, A., Patel, M. I., Lau, H., Woo, H., Bariol, S. & Gurney, H., 21 Jun 2021, In: Asia-Pacific Journal of Clinical Oncology. 9 p.Research output: Contribution to journal › Article › peer-review
-
Safety and tolerability of Miltuximab®: a first in human study in patients with advanced solid cancers
Sabanathan, D., Campbell, D. H., Velonas, V. M., Wissmueller, S., Mazure, H., Trifunovic, M., Poursoltan, P., Shon, K. H., Mackay, T. R., Lund, M. E., Lu, Y., Roach, P. J., Bailey, D. L., Walsh, B. J., Gillatt, D. & Gurney, H., 2021, In: Asia Oceania Journal of Nuclear Medicine and Biology. 9, 2, p. 86-100 15 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile